Hlb Co., Ltd.KRX: 028300

Elevar Therapeutics' NDA Resubmission For Rivoceranib With Camrelizumab Accepted By FDA

· Issued by Hlb Co., Ltd.

Elevar Therapeutics:

  • ELEVAR THERAPEUTICS: ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR RIVOCERANIB IN COMBINATION WITH CAMRELIZUMAB

  • ELEVAR THERAPEUTICS: FDA ASSIGNED PDUFA TARGET ACTION DATE OF JULY 23, 2026